{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:55:43Z","timestamp":1762624543459,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41409-020-01182-w","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T12:05:46Z","timestamp":1610712346000},"page":"1413-1421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9948-660X","authenticated-orcid":false,"given":"R.","family":"Pettengell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Metzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Romejko-Jarosinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bence-Bruckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. U.","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. P.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"P.","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H.","family":"Goldstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"1182_CR1","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood.V128.22.2955.2955","volume":"128","author":"A Alperovich","year":"2016","unstructured":"Alperovich A, Batlevi C, Smith K, Ying Z, Soumerai JD, Copeland AR, et al. Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era. Blood. 2016;128:2955.","journal-title":"Blood"},{"key":"1182_CR2","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: an analysis from the National LymphoCare study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"1182_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","volume":"24","author":"V Jurinovic","year":"2018","unstructured":"Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, et al. Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: a Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant. 2018;24:1172\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1182_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/jnci\/djr450","volume":"104","author":"M Al Khabori","year":"2012","unstructured":"Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104:18\u201328.","journal-title":"J Natl Cancer Inst"},{"key":"1182_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bbmt.2016.01.015","volume":"22","author":"DH Oh","year":"2016","unstructured":"Oh DH, Li H, Duan Q, Villa D, Peters A, Chua N, et al. Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. Biol Blood Marrow Transplant. 2016;22:941\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1182_CR6","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918\u201327.","journal-title":"J Clin Oncol"},{"key":"1182_CR7","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","volume":"96","author":"S Le Gouill","year":"2011","unstructured":"Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, et al. Impact of the use of autologous stem cell transplantation at first relapse both in na\u00efve and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study. Haematologica. 2011;96:1128\u201335.","journal-title":"Haematologica"},{"key":"1182_CR8","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/annonc\/mdu440","volume":"25","author":"I El-Najjar","year":"2014","unstructured":"El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M, et al. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. Ann Oncol. 2014;25:2224\u20139.","journal-title":"Ann Oncol"},{"key":"1182_CR9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/annonc\/mdn691","volume":"20","author":"M Kornacker","year":"2009","unstructured":"Kornacker M, Stumm J, Pott C, Dietrich S, S\u00fcssmilch S, Hensel M, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009;20:722\u20138.","journal-title":"Ann Oncol"},{"key":"1182_CR10","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","volume":"54","author":"RF Duarte","year":"2019","unstructured":"Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe. Bone Marrow Transplant. 2019;54:1525\u201352.","journal-title":"Bone Marrow Transplant"},{"key":"1182_CR11","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/jnci\/djr418","volume":"103","author":"L Vidal","year":"2011","unstructured":"Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103:1799\u2013806.","journal-title":"J Natl Cancer Inst"},{"key":"1182_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","volume":"76","author":"L Vidal","year":"2017","unstructured":"Vidal L, Gafter-Gvili A, Salles G, Bousseta S, Oberman B, Rubin C, et al. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. Eur J Cancer. 2017;76:216\u201325.","journal-title":"Eur J Cancer"},{"key":"1182_CR13","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MHJ van Oers","year":"2010","unstructured":"van Oers MHJ, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853\u20138.","journal-title":"J Clin Oncol"},{"key":"1182_CR14","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","volume":"31","author":"R Pettengell","year":"2013","unstructured":"Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:1624\u201330.","journal-title":"J Clin Oncol"},{"key":"1182_CR15","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1200\/JCO.2011.38.4206","volume":"29","author":"M Buyse","year":"2011","unstructured":"Buyse M, Sargent DJ, Saad ED. Survival is not a good outcome for randomized trials with effective subsequent therapies. J Clin Oncol. 2011;29:4719\u201320.","journal-title":"J Clin Oncol"},{"key":"1182_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","volume":"35","author":"Q Shi","year":"2017","unstructured":"Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, et al. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: an Individual Patient-Level Analysis of Multiple Randomized Trials. J Clin Oncol. 2017;35:552\u201360.","journal-title":"J Clin Oncol"},{"key":"1182_CR17","first-page":"3019","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:3019.","journal-title":"Ann Oncol"},{"key":"1182_CR18","unstructured":"NCCNGuidelines; https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx"},{"key":"1182_CR19","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1200\/JCO.2007.14.4204","volume":"26","author":"C Tarella","year":"2008","unstructured":"Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26:3166\u201375.","journal-title":"J Clin Oncol"},{"key":"1182_CR20","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P, Offner F, L\u00f3pez-Guillermo A, Belada D, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA Study. J Clin Oncol. 2019;37:2815\u201324.","journal-title":"J Clin Oncol"},{"key":"1182_CR21","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","volume":"21","author":"S Montoto","year":"2007","unstructured":"Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, et al. Long-term follow-up of high dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21:2324\u201331.","journal-title":"Leukemia"},{"key":"1182_CR22","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/blood.V87.9.3633.bloodjournal8793633","volume":"87","author":"S Bhatia","year":"1996","unstructured":"Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633\u20139.","journal-title":"Blood"},{"key":"1182_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/annonc\/mdv616","volume":"27","author":"I Fleury","year":"2016","unstructured":"Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol. 2016;27:390\u20137.","journal-title":"Ann Oncol"},{"key":"1182_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2008-02-140616","volume":"113","author":"KJ Cheung","year":"2009","unstructured":"Cheung KJ, Shah SP, Steidl C, Johnson N, Relander T, Telenius A, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood. 2009;113:137\u201348.","journal-title":"Blood"},{"key":"1182_CR25","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128:1112\u201320.","journal-title":"Blood"},{"key":"1182_CR26","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1200\/JCO.2013.52.8190","volume":"32","author":"S Roulland","year":"2014","unstructured":"Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P, et al. t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014;32:1347\u201355.","journal-title":"J Clin Oncol"},{"key":"1182_CR27","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295\u2013301.","journal-title":"Blood"},{"key":"1182_CR28","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00277-016-2705-z","volume":"95","author":"J Bourcier","year":"2016","unstructured":"Bourcier J, Gastinne T, Leux C, Moreau A, Bossard C, Mahe B, et al. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience. Ann Hematol. 2016;95:1287\u201393.","journal-title":"Ann Hematol"},{"key":"1182_CR29","first-page":"715","volume":"5","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance Therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.CIBMTR and LWP-EBMT. J Am Med Assoc Oncol. 2019;5:715\u201322.","journal-title":"J Am Med Assoc Oncol"},{"key":"1182_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ctrv.2017.05.007","volume":"58","author":"L Zhang","year":"2017","unstructured":"Zhang L, Ghielmini M, Cheson BD, Ujjani C. Pros and Cons of rituximab maintenance in follicular lymphoma. Cancer Treat Rev. 2017;58:34\u201340.","journal-title":"Cancer Treat Rev"},{"key":"1182_CR31","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1182\/blood-2015-02-628362","volume":"125","author":"A Rashidi","year":"2015","unstructured":"Rashidi A, Oak E, Bartlett NL. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. Blood. 2015;125:3354\u20135.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01182-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01182-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01182-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:17:22Z","timestamp":1684617442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01182-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1182"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01182-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}